Israel’s EXO-CD24 Now to Enter Imminent COVID-19 Clinical Trial Led by Greece’s Top Infectious Disease Expert

Israel’s EXO-CD24 Now to Enter Imminent COVID-19 Clinical Trial Led by Greece’s Top Infectious Disease Expert

Earlier this year, TrialSite reported on a novel cancer drug known as EXO-CD24 under development at Tel Aviv Sourasky Medical Center (Ichilov Hospital) that demonstrated compelling results. Led by Professor Nadir Arber, the study resulted from “out-of-the-box” thinking that led to surprising results: 29 out of 30 patients with moderate-to-severe COVID-19 that participated in the study involving EXO-CD24 recovered from COVID-19 within three to five days. This result, TrialSite reported, created real buzz in Israeli research circles and beyond. Now Sotiris Tsiodras, prominent infectious disease clinical investigator in Greece, has joined the research. He and Nadir Arber, Professor of Medicine at the Tel Aviv Medical Center (and head of Cancer Prevention Center), met in Greece along with Prime Minister Kyriakos Mitsotakis at the Maximos Palace. The day before, the prominent Israeli researcher met the Greek Deputy Minister of Health, Vassilis Kontozamanis and Professor Sotiris Tsiodras at Attikon Hospital. Excited about the potential of this Israeli-developed drug, the Minister of Health commented, “We are optimistic that it will contribute effectively to the fight against the pandemic.” The Greeks informed the visiting Israeli that a new clinical trial here was to commence investigating EXO-CD24.

Greece just experienced another major wave much like other nations have in Europe. With about 10.4 million people living in Greece, the country has an estimated 346,000 COVID-19 cases and over 10,000 deaths.

Reported recently in Greek City Times, the Greek contingent is upbeat about the results at the Ichilov Medical Center in Tel Aviv where in the small preliminary study the results showed a 96% efficacy rate for the inhaled drug originally developed by Professor Arber for ovarian cancer.  

Therapies Necessary

Professor Arbor told his Greek hosts that “even if the vaccines do their job, even if there are no new mutations, one way or another the coronavirus will stay with us.” Hence the importance of a therapeutic such as this the Israeli research shared in Greece.

Lead Research/Investigator in Greece

Sotiris Tsiodras, MD, specialist in infectious diseases

Call to Action: TrialSite is tracking EXO-CD24 as it demonstrates considerable early stage promise as a therapeutic target against COVID-19.